1. Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic
- Author
-
Benjamin Marchandot, Olivier Morel, Antonin Trimaille, Kensuke Matsushita, Laurence Jesel, Anais Curtiaud, Nouvel Hôpital Civil de Strasbourg, CHU Strasbourg, Nanomédecine Régénérative (NanoRegMed), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), and univOAK, Archive ouverte
- Subjects
Male ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Pneumonia, Viral ,Disease ,Guidelines ,030204 cardiovascular system & hematology ,Article ,Betacoronavirus ,03 medical and health sciences ,0302 clinical medicine ,Fibrinolytic Agents ,Risk Factors ,Thromboembolism ,Research community ,Pandemic ,medicine ,Coagulopathy ,Humans ,In patient ,030212 general & internal medicine ,Thromboprophylaxis ,Intensive care medicine ,Blood Coagulation ,Pandemics ,Aged ,Aged, 80 and over ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,SARS-CoV-2 ,business.industry ,Anticoagulants ,COVID-19 ,Hematology ,Middle Aged ,medicine.disease ,3. Good health ,Coronavirus ,Treatment Outcome ,Host-Pathogen Interactions ,Female ,Coronavirus Infections ,Cardiology and Cardiovascular Medicine ,business ,Venous thromboembolism ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Fibrinolytic agent - Abstract
A common and potent consideration has recently entered the landscape of the novel coronavirus disease of 2019 (COVID-19): venous thromboembolism (VTE). COVID-19 has been associated to a distinctive related coagulopathy that shows unique characteristics. The research community has risen to the challenges posed by this « evolving COVID-19 coagulopathy » and has made unprecedented efforts to promptly address its distinct characteristics. In such difficult time, both national and international societies of thrombosis and hemostasis released prompt and timely responses to guide recognition and management of COVID-19-related coagulopathy. However, latest guidelines released by the international Society on Thrombosis and Haemostasis (ISTH) on May 27, 2020, followed the American College of Chest Physicians (CHEST) on June 2, 2020 showed some discrepancies regarding thromboprophylaxis use. In this forum article, we would like to offer an updated focus on thromboprophylaxis with current incidence of VTE in ICU and non-ICU patients according to recent published studies; highlight the main differences regarding ISTH and CHEST guidelines; summarize and describe which are the key ongoing RCTs testing different anticoagulation strategies in patients with COVID-19; and finally set a proposal for COVID-19 coagulopathy specific risk factors and dedicated trials.
- Published
- 2020
- Full Text
- View/download PDF